drugset
drugset / Trial / NCT00795639

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639 ↗

Phase 3 Terminated 183 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.

Timeline

Start
2008-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitaxentan Small molecule 100 mg Oral

Indications

pulmonary arterial hypertension